TY - JOUR
T1 - Screening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models
AU - Zorzan, Eleonora
AU - Da Ros, Silvia
AU - Musetti, Caterina
AU - Shahidian, Lara Zorro
AU - Coelho, Nuno Filipe Ramos
AU - Bonsembiante, Federico
AU - Létard, Sébastien
AU - Gelain, Maria Elena
AU - Palumbo, Manlio
AU - Dubreuil, Patrice
AU - Giantin, Mery
AU - Sissi, Claudia
AU - Dacasto, Mauro
PY - 2016/4/19
Y1 - 2016/4/19
N2 - Stabilization of G-quadruplex (G4) structures in promoters is a novel promising strategy to regulate gene expression at transcriptional and translational levels. c-KIT proto-oncogene encodes for a tyrosine kinase receptor. It is involved in several physiological processes, but it is also dysregulated in many diseases, including cancer. Two G-rich sequences able to fold into G4, have been identified in c-KIT proximal promoter, thus representing suitable targets for anticancer intervention. Herein, we screened an "in house" library of compounds for the recognition of these G4 elements and we identified three promising ligands. Their G4-binding properties were analyzed and related to their antiproliferative, transcriptional and post-transcriptional effects in MCF7 and HGC27 cell lines. Besides c-KIT, the transcriptional analysis covered a panel of oncogenes known to possess G4 in their promoters. From these studies, an anthraquinone derivative (AQ1) was found to efficiently downregulate c-KIT mRNA and protein in both cell lines. The targeted activity of AQ1 was confirmed using c-KIT-dependent cell lines that present either c-KIT mutations or promoter engineered (i.e., α155, HMC1.2 and ROSA cells). Present results indicate AQ1 as a promising compound for the target therapy of c-KIT-dependent tumors, worth of further and in depth molecular investigations.
AB - Stabilization of G-quadruplex (G4) structures in promoters is a novel promising strategy to regulate gene expression at transcriptional and translational levels. c-KIT proto-oncogene encodes for a tyrosine kinase receptor. It is involved in several physiological processes, but it is also dysregulated in many diseases, including cancer. Two G-rich sequences able to fold into G4, have been identified in c-KIT proximal promoter, thus representing suitable targets for anticancer intervention. Herein, we screened an "in house" library of compounds for the recognition of these G4 elements and we identified three promising ligands. Their G4-binding properties were analyzed and related to their antiproliferative, transcriptional and post-transcriptional effects in MCF7 and HGC27 cell lines. Besides c-KIT, the transcriptional analysis covered a panel of oncogenes known to possess G4 in their promoters. From these studies, an anthraquinone derivative (AQ1) was found to efficiently downregulate c-KIT mRNA and protein in both cell lines. The targeted activity of AQ1 was confirmed using c-KIT-dependent cell lines that present either c-KIT mutations or promoter engineered (i.e., α155, HMC1.2 and ROSA cells). Present results indicate AQ1 as a promising compound for the target therapy of c-KIT-dependent tumors, worth of further and in depth molecular investigations.
KW - Anthraquinone
KW - C-KIT
KW - G-quadruplex
KW - G4-ligands
KW - In-vitro models
UR - http://www.scopus.com/inward/record.url?scp=84965044051&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.7808
DO - 10.18632/oncotarget.7808
M3 - Article
C2 - 26942875
AN - SCOPUS:84965044051
SN - 1949-2553
VL - 7
SP - 21658
EP - 21675
JO - Oncotarget
JF - Oncotarget
IS - 16
ER -